Why the study?
Does sacubitril-valsartan improve clinical outcomes and maintain safety compared to enalapril in patients with HFrEF?
Does sacubitril-valsartan improve clinical outcomes and maintain safety compared to enalapril in patients with HFrEF?
Sacubitril-valsartan provides significant clinical benefits in HFrEF, though long-term safety regarding angioedema and neurocognitive risks requires ongoing surveillance.
Answers are grounded in this paper and cite their sources.
Supports comparable tolerability to controls in HFrEF; leaves open questions on long-term safety in diverse real-world cohorts.
INTRODUCTION: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug Administration approved sacubitril-valsartan for treatment of heart failure patients with reduced ejection fraction and New York Heart Association class II-IV symptoms following a large, Phase III clinical trial (PARADIGM-HF) that demonstrated a 20% reduction in the combined primary end-point of death from cardiovascular cause or hospitalization for heart failure compared to enalapril. Areas covered: This review discusses the clinical efficacy and safety of angiotensin receptor neprilysin inhibitor sacubitril-valsartan in heart failure with reduced ejection fraction. Expert opinion: Based on the PARADIGM-HF trial, sacubitril-valsartan offers compelling reductions in meaningful clinical endpoints, independent of age or severity of disease. The rate of adverse events was comparable between the enalapril and sacubitril-valsartan groups, although the absolute rates are likely underestimated due to the entry criteria and run-in period. Future trials and post-market surveillance are critical to better understand the risk of angioedema in high risk populations, particularly African-Americans, as well as long-term theoretical risks including the potential for increased cerebral amyloid plaque deposition with possible development of neurocognitive disease. Current trials are underway to evaluate potential benefit in patients with heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Tyler et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: